MBOT · Microbot Medical Inc.

This 8-K discloses early commercial validation for Microbot Medical’s LIBERTY Endovascular Robotic System following its Full Market Release at the Society of Interventional Radiology (SIR) annual meeting. The adoption by two sites that previously participated in the ACCESS-PVI pivotal clinical trial is a notable signal of real-world clinical confidence and reduces perceived adoption risk among peers. The timing aligns with updated medical guidelines emphasizing radiation reduction and ergonomic improvements—factors cited in the filing as contributors to growing commercial interest. Participation in the upcoming GEST conference represents a strategic inflection point: it is the first major global forum featuring LIBERTY since full market launch, and attendance by over 1,000 IR/IO specialists offers high-impact peer-to-peer exposure. The appointment of Alon Tamir as VP of Sales, EMEA, further signals intent to scale internationally in H2 2026—not as aspirational commentary but as an operational milestone tied to infrastructure development. While no financial metrics, revenue figures, or guidance are disclosed, the progression from clinical trial participation to commercial account wins—and the explicit linkage to guideline-driven demand—constitutes meaningful forward momentum for a commercial-stage medtech company with a novel single-use robotic platform.